In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...
Johnson & Johnson is a picture of stability.
As a global giant in the healthcare industry, Johnson & Johnson is renowned for its stable operating history spanning over a century. The company has achieved numerous milestones throughout its ...
Major global pharmaceutical companies are significantly boosting their U.S. manufacturing capacities in response to potential ...
Jan 30 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded and patented medicines.
Pfizer PFE is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $16.93 ...
Pfizer is exiting its HIV-focused joint venture, ViiV Healthcare, while reshaping its portfolio around other therapeutic ...
Analysts fell to the sidelines weighing in on Pfizer (PFE – Research Report) and Sundrug Co (SDGCF – Research Report) with neutral ratings, indicating that the experts are nei ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results